Cargando…

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer

PURPOSE: This study aimed to evaluate the feasibility and tolerability of biweekly docetaxel with capecitabine as first-line treatment in advanced gastro-oesophageal cancer. METHODS: Fifty-three patients at median age of 61 years with advanced gastric cancer were included in this prospective, non-ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korkeila, E. A., Salminen, T., Kallio, R., Mikkola, M., Auvinen, P., Pyrhönen, S., Ristamäki, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527066/ https://www.ncbi.nlm.nih.gov/pubmed/28424889 http://dx.doi.org/10.1007/s00520-017-3689-5

Ejemplares similares

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Gastro-Œsophageal Intussusception
Publicado: (1935)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Association of gastro-oesophageal reflux disease and quality of life in patients with chronic rhinosinusitis
por: Xu, Yang, et al.
Publicado: (2021)

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
por: Birkman, Eva-Maria, et al.
Publicado: (2016)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
por: Baxter, Mark A., et al.
Publicado: (2021)

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009)

The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer
por: McKernan, M, et al.
Publicado: (2008)

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
por: Pinto, C, et al.
Publicado: (2009)

Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Gastro-oesophageal reflux disease and eosinophilic oesophagitis: What is the relationship?
por: Wong, Stephanie, et al.
Publicado: (2018)

Sensory Phenotype of the Oesophageal Mucosa in Gastro-Oesophageal Reflux Disease
por: Ustaoglu, Ahsen, et al.
Publicado: (2023)

Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis
por: Akiyama, Yuji, et al.
Publicado: (2018)

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial
por: Lorenzen, S, et al.
Publicado: (2005)

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
por: Oh, S C, et al.
Publicado: (2007)

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
por: Chao, Yee, et al.
Publicado: (2014)

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2011)

Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer
por: Gaast, A van der, et al.
Publicado: (1999)

Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors
por: Vošmik, Milan, et al.
Publicado: (2021)

Gastro-Oesophageal Reflux in Noncystic Fibrosis Bronchiectasis
por: Lee, Annemarie L., et al.
Publicado: (2011)

Is gastro-oesophageal reflux associated with COPD exacerbations?
por: Wedzicha, Jadwiga A.
Publicado: (2013)

Feed thickeners in gastro-oesophageal reflux in infants
por: Kwok, T’ng Chang, et al.
Publicado: (2018)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology – an update for the surgical oncologist
por: Griffiths, Ewen A, et al.
Publicado: (2006)

Complete Remission of Advanced Gastric Cancer in Response to Chemotherapy With Docetaxel, Cisplatin and Capecitabine (dcx)
por: Marroqui, Asuncion Juarez, et al.
Publicado: (2011)

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
por: Dermanis, Alexander A., et al.
Publicado: (2023)

Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI
por: Sharkey, Amy R., et al.
Publicado: (2021)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
por: Wu, C, et al.
Publicado: (2015)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
por: Eatock, M M, et al.
Publicado: (2000)

Gastro-oesophageal reflux disease in children: NICE guidance
por: Davies, Ieuan, et al.
Publicado: (2015)

Carcinoma of gastro-oesophageal junction in a pregnant woman
por: Kozak, Katarzyna, et al.
Publicado: (2018)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
por: Thuss-Patience, P C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_usaopd60pljvhmrn5odql0qluv